In the meta-analysis there was no significant difference in all-cause mortality (RR: 0.89, 95% CI: 0.76 -1.04, P ¼ 0.979) between AT and PPCI arm at 1-month (RR: 0.89, 95% CI: 0.76 -1.04, P ¼ 0.155), 6-12 months (RR: 0.87, 95% CI: 0.38 -1.98, P ¼ 0.620) and >12 months (RR: 0.73, 95% CI: 0.49 -1.09, P ¼ 0.12) follow-up. The 2 groups were similar with regards to target vessel revascularization (RR: 0.79, 95% CI: 0.60 -1.04, P ¼ 0.149) and stroke (RR: 1.45, 95% CI: 0.84 -2.50, P ¼ 0.620) however there was a significant reduction of recurrent MI (RR: 0.67, 95% CI: 0.46 -0.97, P ¼ 0.032) and MACE (Death þ MI þ target vessel revascularization) rate (RR: 0.81, 95% CI: 0.66 -0.99, P ¼ 0.031) in AT arm when compared to PPCI. The net clinical benefit (MACE þ stroke) was similar in the two groups (RR: 0.97, 95% CI: 0.87 -1.07, P ¼ 0.710).
available randomized controlled trial ,we show that AT prior to PPCI in STEMI is associated with similar mortality, stroke and target revascularization rates however there is a significant reduction of MACE rate in the AT arm primarily driven by reduced rates of recurrent MI. There was no difference between the two treatment arms in terms of net clinical benefit. METHODS Twenty-four pigs were randomly assigned to 3 groups: normothermia 38 C, mild hypothermia 35 C and moderate hypothermia 32 C. MI was induced by 1-hour balloon occlusion of the mid LAD followed by reperfusion. A heat-exchange balloon catheter placed in the inferior vena cava controlled core temperature. Cooling was initiated 30 minutes after occlusion and maintained for 1 hour followed by rewarming to normothermia. IS was assessed at day 6 with magnetic resonance imaging (CMR) and pathology (TTC).
RESULTS Target temperature was reached in 9AE5 and 29AE8 minutes for 35 C and 32 C, respectively. Area-at-risk (AAR) from TTC staining was equivalent in all groups (30AE6, 28AE7, 26AE6, ANOVA p¼0.217). Both the 32 C and 35 C showed significant IS reduction per AAR (45AE12, 17AE11, 4AE3, 62% and 91% reduction, respectively, p<0.001) and a similar reduction per LV mass (14AE5, 5AE3, 1AE1, p<0.001). Further, 32 C showed a significant 76% IS per AAR reduction relative to 35 C (p¼0.013) suggesting additional tissue salvage from deeper cooling. In the linear regression model, target temperature was a significant predictor of IS reduction both per AAR and LV (R2¼ 0.746 and 0.685, respectively, p<0.001). The predicted infarct reduction is 7% of AAR and 2% of LV per 1 C drop at reperfusion. Additionally, 32 C had less variability compared to 35C in reducing IS (standard deviation 3 vs 10 relative to AAR and 1 vs 3 relative to LV). In-vivo CMR imaging evaluation also supported results of significant IS reduction with 32 C (10AE4*, 8AE3, 3AE2*, *p<0.001). Cardiac output relative to baseline was significantly preserved in 32C only (-30%AE19*, -17%AE32, -1%AE28*, *p¼0.041). Both 35 C and 32 C exhibited significant reductions in T2 edema suggesting reduced injury with hypothermia (p<0.05).
CONCLUSIONS Pre-reperfusion rapid therapeutic hypothermia shows a dose-response infarct size reduction as well as favorable hemodynamic outcomes for moderate hypothermia more consistently than mild hypothermia. 
